65,437 trials
BK Virus (BKV) Viremia
Primary: Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects — 58 Participants
Accidental Fall
Primary: The Berg Balance Scale (BBS) — 40.63; 35.25; 38.38; 35.88 score on a scale
Heart Failure · Cardiac Failure · Reduced Ventricular Ejection Fraction
Primary: Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231…
Cognitive Dysfunction
Primary: Change in Trail Making Test (TMT) B Between Baseline and End of Treatment — -17.63; 3.46 seconds — p=0.0000
Type 1 Diabetes
Primary: Change in GAD65 Autoantibody Titer (DK Units/mL) — 247; 234; 193; 196 DK Units/mL
Varicose Veins
Primary: Patient's Post-procedure Pain Score Using a Visual Analogue Scale (VAS) — 18.7; 27.8 mm
Vasculitis
Primary: Proportion of Subjects Achieving Disease Response at Day 85 — 0.7; 0.86; 0.81 proportion of participants
Liver Damage
Primary: Patient Survival at One Year Post-Transplantation — 19; 19 participants
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
Fibromyalgia
Primary: fcMRI as a Biomarker to Investigate Functionally Correlated Neural Substrates of Pain in Patients Undergoing PENFS — 0; 0; 0; 0 Cluster size (voxels) — p=<0.05
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 39.4; 43.3 Percentage of participants
Head and Neck Cancer
Primary: Feasibility of TFRT Planning and Delivery Defined by Number of Participants Starting Radiotherapy Within 15 Days of Simulation — 4 Participants
Postoperative Complications · Obesity · Gynecologic Neoplasms
Primary: Number of Participants Who Experience Wound Complications (Wound Dehiscence or Infection) — 25; 33; 12; 9 Participants — p=0.27
Alcohol Dependence
Primary: Percentage of Heavy Drinking Days (HDD%) During the Full Dose Period From Weeks 3-12 — 8.2; 27.11; 31.29; 7.32 percentage of heavy drinking days — p=0.016
Vaginal Infection
Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 18 Participants — p=<0.001